Raloxifene 6-glucuronide Catalog No.:M13237-10 InChi: InChI=1S/C9H9ClO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-3

InChi: InChI=1S/C9H9ClO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-3

Because baseline paw volume measurements are taken on treatment day 0-in animals with significant signs of disease-it is possible to have >100% inhibition in animals showing marked improvement in swelling[1]

is a potent neuroprotective antioxidant and plant auxin

S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum

48 hours) treatment markedly suppresses the expression of vascular endothelial (VE)-cadherin in a dose-dependent manner and also slightly diminishes the expression of Sema4D in C8161 cells

Raloxifene 6-glucuronide Catalog No.:M13237-10 InChi: InChI=1S/C9H9ClO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-3Raloxifene 6 glucuronide is a primary metabolite of Raloxifene. Raloxifene 6 glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6 glucuronide binds to estrogen receptor with an IC50 of 290 M. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGF3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element containing vitellogenin promoter expression. Product